Aldeyra Therapeutics, Inc.
ALDX
$2.65
-$0.015-0.56%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.24% | 42.78% | -10.11% | -42.34% | -62.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 171.87% | 68.97% | 74.11% | -44.09% | -55.48% |
| Operating Income | -171.87% | -68.97% | -74.11% | 44.09% | 55.48% |
| Income Before Tax | -232.61% | -84.60% | -87.47% | 48.24% | 63.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -232.61% | -84.60% | -87.47% | 48.24% | 63.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -232.61% | -84.60% | -87.47% | 48.24% | 63.16% |
| EBIT | -171.87% | -68.97% | -74.11% | 44.09% | 55.48% |
| EBITDA | -173.80% | -69.47% | -74.60% | 44.23% | 55.75% |
| EPS Basic | -230.39% | -82.93% | -85.48% | 48.80% | 63.55% |
| Normalized Basic EPS | -230.28% | -83.04% | -85.55% | 48.80% | 63.54% |
| EPS Diluted | -230.39% | -82.93% | -85.48% | 48.80% | 63.55% |
| Normalized Diluted EPS | -230.28% | -83.04% | -85.55% | 48.80% | 63.54% |
| Average Basic Shares Outstanding | 0.65% | 0.92% | 1.06% | 1.06% | 1.08% |
| Average Diluted Shares Outstanding | 0.65% | 0.92% | 1.06% | 1.06% | 1.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |